FDA must abandon 'blanket approach' to phytosterol claims, argue firms
Three more firms have followed Cargill’s lead and submitted petitions to the FDA urging it to rethink plans to amend the criteria for making health claims about phytosterols and heart disease or risk causing “irreparable injury”.